384 related articles for article (PubMed ID: 17123853)
1. [Proteomics and breast cancer].
Mathelin C; Tomasetto C; Cromer A; Rio MC
Gynecol Obstet Fertil; 2006 Dec; 34(12):1161-9. PubMed ID: 17123853
[TBL] [Abstract][Full Text] [Related]
2. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
3. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
Zhang GQ; Du J; Pang D
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
[TBL] [Abstract][Full Text] [Related]
4. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
5. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
6. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
Solassol J; Marin P; Maudelonde T; Mangé A
Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
[TBL] [Abstract][Full Text] [Related]
7. SELDI-TOF serum proteomics and breast cancer: which perspective?
Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic application of serum protein pattern and artificial neural network software in breast cancer].
Hu Y; Zhang SZ; Yu JK; Liu J; Zheng S; Hu X
Ai Zheng; 2005 Jan; 24(1):67-71. PubMed ID: 15642203
[TBL] [Abstract][Full Text] [Related]
9. Use of serological proteomic methods to find biomarkers associated with breast cancer.
Rui Z; Jian-Guo J; Yuan-Peng T; Hai P; Bing-Gen R
Proteomics; 2003 Apr; 3(4):433-9. PubMed ID: 12687611
[TBL] [Abstract][Full Text] [Related]
10. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
11. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
12. [Serum diagnosis of head and neck squamous cell carcinoma using surface-enhanced desorption ionization mass spectrometry and artificial neural network analyses].
Cao SM; Guo X; Chen FJ; Yang AK; Chen WK; Li NW
Ai Zheng; 2007 Jul; 26(7):767-70. PubMed ID: 17626756
[TBL] [Abstract][Full Text] [Related]
13. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Engwegen JY; Gast MC; Schellens JH; Beijnen JH
Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
[TBL] [Abstract][Full Text] [Related]
14. [Identification of colorectal cancer using proteomic patterns in serum].
Zhao G; Gao CF; Song GY; Li DH; Wang XL
Ai Zheng; 2004 Jun; 23(6):614-8. PubMed ID: 15191657
[TBL] [Abstract][Full Text] [Related]
15. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
16. Proteomic patterns: their potential for disease diagnosis.
Xiao Z; Prieto D; Conrads TP; Veenstra TD; Issaq HJ
Mol Cell Endocrinol; 2005 Jan; 230(1-2):95-106. PubMed ID: 15664456
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.
Park Y; Downing SR; Kim D; Hahn WC; Li C; Kantoff PW; Wei LJ
Bioinformatics; 2007 Jun; 23(12):1451-8. PubMed ID: 17459967
[TBL] [Abstract][Full Text] [Related]
18. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Gonçalves A; Bertucci F; Birnbaum D; Borg JP
Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
[TBL] [Abstract][Full Text] [Related]
19. Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples.
van der Werff MP; Mertens B; de Noo ME; Bladergroen MR; Dalebout HC; Tollenaar RA; Deelder AM
Stat Appl Genet Mol Biol; 2008; 7(2):Article2. PubMed ID: 18241195
[TBL] [Abstract][Full Text] [Related]
20. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.
El-Aneed A; Banoub J
Anticancer Res; 2006; 26(5A):3293-300. PubMed ID: 17094443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
